Vanguard Group Inc. Sells 472,765 Shares of Progyny, Inc. $PGNY

Vanguard Group Inc. lessened its holdings in Progyny, Inc. (NASDAQ:PGNY) by 4.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,633,382 shares of the company’s stock after selling 472,765 shares during the quarter. Vanguard Group Inc. owned 0.11% of Progyny worth $247,385,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Federated Hermes Inc. boosted its position in shares of Progyny by 147.3% in the third quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock valued at $30,000 after acquiring an additional 819 shares during the period. Versant Capital Management Inc boosted its position in shares of Progyny by 61.8% in the third quarter. Versant Capital Management Inc now owns 2,340 shares of the company’s stock valued at $50,000 after acquiring an additional 894 shares during the period. Covestor Ltd boosted its position in shares of Progyny by 164.9% in the third quarter. Covestor Ltd now owns 2,609 shares of the company’s stock valued at $56,000 after acquiring an additional 1,624 shares during the period. Quarry LP boosted its position in shares of Progyny by 2,004.1% in the third quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after acquiring an additional 3,427 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Progyny in the second quarter valued at about $77,000. Institutional investors own 94.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on PGNY shares. Canaccord Genuity Group reduced their target price on shares of Progyny from $26.00 to $19.00 and set a “hold” rating for the company in a research report on Wednesday, March 11th. Barclays reduced their target price on shares of Progyny from $29.00 to $23.00 and set an “overweight” rating for the company in a research report on Friday, March 20th. Citizens Jmp raised Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price target for the company in a research note on Tuesday, January 20th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $30.00 price target on shares of Progyny in a research note on Friday, March 6th. Finally, Truist Financial dropped their price target on Progyny from $34.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $27.91.

Progyny Stock Up 23.8%

PGNY stock opened at $23.72 on Friday. The company has a market cap of $1.86 billion, a PE ratio of 30.81, a price-to-earnings-growth ratio of 1.10 and a beta of 0.91. The business has a 50-day simple moving average of $17.87 and a 200 day simple moving average of $21.69. Progyny, Inc. has a 52 week low of $16.10 and a 52 week high of $28.75.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.03. The business had revenue of $328.50 million during the quarter, compared to the consensus estimate of $326.47 million. Progyny had a return on equity of 12.76% and a net margin of 5.23%.Progyny’s revenue for the quarter was down 26.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, analysts anticipate that Progyny, Inc. will post 1.12 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Allison Swartz sold 4,657 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total value of $81,031.80. Following the completion of the transaction, the executive vice president owned 89,879 shares of the company’s stock, valued at $1,563,894.60. The trade was a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 7,455 shares of company stock valued at $129,515 over the last three months. 9.90% of the stock is owned by insiders.

Key Progyny News

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny beat Q1 estimates, reporting $0.50 adjusted EPS versus $0.44 expected and revenue of $328.5 million versus $326.5 million forecast, helping reinforce the stock’s move higher. Progyny, Inc. Announces First Quarter 2026 Results
• Positive Sentiment: The company raised second-quarter and full-year 2026 guidance, with Q2 EPS outlook of $0.50 to $0.53 and FY2026 EPS guidance of $1.98 to $2.09, both above Wall Street estimates, which supports confidence in future earnings power. Conference call and earnings materials
• Positive Sentiment: Management said early selling-season activity and member engagement were strong, and the company highlighted continued share repurchases, with 8.8 million shares bought back since November, adding another supportive signal for investors. Progyny, Inc. Announces First Quarter 2026 Results
• Neutral Sentiment: Revenue was still down 26.4% year over year, so while the quarter beat expectations, investors may remain focused on whether growth can stabilize after the recent decline. Progyny: Q1 Earnings Snapshot
• Neutral Sentiment: Some commentary noted concern around flat revenue guidance, which could temper the bullish reaction if investors want clearer top-line acceleration going forward. The Bull Case For Progyny (PGNY) Could Change Following Flat Q1 2026 Revenue Guidance Concerns

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.